Fouremm & others ... I agree that mgt has done a poor job regarding shareholder value, and not taking advantage of the "good" things that have been accomplished to date. Any thoughts or ideas regarding "why" the BoD (ok maybe they're puppets in the RVX kangaroo court) and entities like Eastern, Hepa, Ori, and "maybe" the Sheikh seem encouraged, happy, or at least continually going along with Don's leadership? Beyond just throwing their hands up and saying "what the heck else can we do at this point, in for a pound in for a dollar"??

Normally, I wouldn't be shocked with strong compensation for the leaders of this type of biotech investment along the journey, except this has been an exceptionally long journey, with many short falls, and missed milestones and timelines ... not sure it makes sense to make their compenasation too overly incentive laden as we want the correct deal more than just simply a fast deal, but it would seem appropriate at this point to migrate the comp value toward incentives in order to help get something done.

I wouldn't be in favor of fully sacking Don, but I would be in favor of bringing in a younger lion CEO or CCO that has some fire & experience in this area, and at this point in the growth curve. Still lamenting the lack of a BP deal, specifically for the extra leadership in addition to the cash and credibility.

We need some good Covid results, and to get BoM2 moving ... if we aren't getting a BP deal hanging just around the corner.